COMP <GO>
XRAY vs JNJ // 10Y YIELD & FRED MACRO BETA
DENTSPLY SIRONA Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: XRAY 2
— JNJ 9
■ METRIC PARITY
LAST: $9.61 (+1.80%) • MKT CAP: $1.92B
macro-sensitivity
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XRAY VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XRAY | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.00% | 67.90% | -17.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.00% | 25.50% | -36.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.27% | 2.97% | +9.30 | XRAY | /fcf-yield <GO> |
| Operating Margin | -11.50% | 34.70% | -46.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -16.20% | 28.50% | -44.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 6.00% | -9.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 6.68% | 0.00% | +6.68 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.59 | -5.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.5 | 62.1 | -5.60 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.92B | $662.49B | -$660.58B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XRAY REV | JNJ REV | XRAY GROSS % | JNJ GROSS % | XRAY FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.68B | $94.19B | 50.0% | 67.9% | $235.0M | $19.70B |
| FY 2024 | $3.79B | $88.82B | 51.6% | 69.1% | $461.0M | $19.84B |
| FY 2023 | $3.96B | $85.16B | — | — | $377.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XRAY // BETA —
JNJ // BETA 1.08